Company Overview
Company Type: Private Company
Website: www.veristat.com
Global Number of Employees (Latest): 300
Year Founded: 1994
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Veristat, LLC, a clinical research organization, supports clinical trials for pharmaceutical, biotechnology, and medical device companies. It offers support services, such as strategic consulting, regulatory affairs, clinical operations, medical affairs, medical writing, biometrics, full service, and pharmacovigilance in various therapeutic areas, including oncology, infectious disease, neurology, cardiovascular disease, coronavirus, and other therapy areas. The company also provides solutions in the areas of cell and gene therapies, virtual trials, rare diseases, rescue trials, and vaccine trials. It serves customers ranging from small to large global companies, and clients engage in the development of new pharmaceutical and biological products, vaccines, medical devices, and diagnostic agents. Veristat, LLC was founded in 1994 and is based in Southborough, Massachusetts with additional offices in Morrisville, North Carolina; Knutsford, United Kingdom; Barcelona, Spain; Basel, Switzerland; and Taipei, Taiwan.


Financial Information (Currency: CAD, in mm)
Total Revenue
 50.4
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
 300
Net Debt
-
U.S. Number of Employees 2023
 231
U.S. Number of Employees 2022
 219
U.S. Last Year Employee Growth %
 5.5
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Flanagan, Patrick 
Chief Executive Officer
Balser, John P.
Co-Founder, President & Chief Statistical Officer
Balser, Barbara 
Co-Founder, Chief Scientific Officer & Executive VP
Scott, Joe 
Chief Financial Officer
Shao, Nan 
Executive Vice President of Global Operations
Brennan, Lauren L.
Vice President of Marketing
Furst-Ladani, Shayesteh 
Senior VP of SFL & Head of SFL Group
Grassis, Natalia 
Executive Vice President Global Clinical Operations & Delivery
Henderson, Cindy 
Chief Commercial Officer
Lukis, Lindsey 
Executive Vice President of Talent & Culture
Madichie, Elizabeth R.
Executive Vice President of Global Regulatory Affairs
Pelton, Colleen 
Chief Talent Officer


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
134 Turnpike Road Suite 200 | Southborough, MA | 01772 | United States
Phone: 508 429 7340   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
WindRose Health Investors, LLC
Apr-07-2021
Majority
-
-
C. Hall, Christopher Burnes
Brooke Private Equity Associates Management LLC
-
Unknown
-
-
-

Prior Investors
Variance Development Partners


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Scinopsis SARL
Scinopsis SARL offers sundry professional, scientific, and technical activities. The company was incorporated in 2006 and is based in Frejus, France. As of June 12, 2023, Scinopsis operates as a subsidiary of Veristat, LLC.

Europe
Research and Consulting Services
-
-
-
SFL Regulatory Affairs & Scientific Communication GmbH
SFL Regulatory Affairs & Scientific Communication GmbH operates as a consultancy that provides integrated solutions to pharma, biotech, and medtech companies for global and local activities. The company was incorporated in 2009 and is based in Basel, Switzerland. As of March 7, 2022, SFL Regulatory Affairs & Scientific Communication GmbH operates as a subsidiary of Veristat, LLC.

Europe
Research and Consulting Services
-
-
-
Drug Development and Regulation, SL
Drug Development and Regulation, SL operates as a consultancy company focused on providing appropriate scientific and regulatory expertise for the global development and registration of drugs and medical devices. The company was incorporated in 2013 and is based in Barcelona, Spain. As of November 11, 2021, Drug Development and Regulation, SL operates as a subsidiary of Veristat, LLC.

Europe
Life Sciences Tools and Services
-
-
-
Sqn Clinical Limited
SQN Clinical Limited operates as a holding, patent owners, and trusts or estates company. It provides activities of holding companies. It was founded in 1996 and is based in Diss, United Kingdom.

Europe
Multi-Sector Holdings
-
-
-
Hawkins Point Partners LLC
Hawkins Point Partners LLC provides process engineering, system integration and architecture, information management, software engineering, and project management services. The company offers delivery management, including business analysis, enterprise and data architecture, and software engineering services; process engineering, including program governance, requirements management, business process improvement, and IT service management services; and security services, which include data and application security, identity and access management, and strategy, risk, and compliance services. It also provides system integration and architecture services, which include enterprise resource planning, customer relationship management, human capital management, and content management services. The company caters to life sciences, government, Hi-tech, financial services, and healthcare industries. Hawkins Point Partners LLC was founded in 2012 and is based in North Chelmsford, Massachusetts. As per the transaction announced on February 2, 2021, Hawkins Point Partners LLC operates as a subsidiary of Veristat, Inc.

United States and Canada
IT Consulting and Other Services
8.00
-
-
Certus PV Services Inc. (Pending)
Certus PV Services Inc. offers pre-approval and post-marketing pharmacovigilance and safety monitoring support for drug developers. The company was founded in 2014 and is headquartered in Mississauga, Canada.

United States and Canada
Life Sciences Tools and Services
-
-
-
The Clinical Trial Company Limited
The Clinical Trial Company Limited operates as a clinical contract research organization. It offers strategic development services; project management services, including protocol writing, investigator brochure preparation, ethics committee and regulatory submission documents, and clinical trial monitoring; pre-clinical services, including assessment of medical device products, and safety testing of pharmaceuticals and drug device combinations; and clinical services, including project management, CRF monitoring, and medical monitoring. The company also provides regulatory affairs services; core labs services, including ECG, QCA, IVUS, and central laboratory services; medical writing and reporting services, including protocol, investigator brochure writing, annual safety reports, and clinical study reports; and biometrics services, including statistics and data management services. It provides services in the therapeutic areas, including cardiology, haematology, dermatology, urology, oncology, trichology, endocrinology, respiratory, CNS, ophthalmology, hyperlipidaemia, immunolog, dental, and vaccines. The company was founded in 2002 and is headquartered in Knutsford, the United Kingdom. It has regional offices in Toronto and Montreal, Canada; and Sydney and Perth, Australia. As of January 6, 2020, The Clinical Trial Company Limited operates as a subsidiary of Veristat, Inc.

Europe
Life Sciences Tools and Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-12-2023
Jun-12-2023
Merger/Acquisition
Buyer
Scinopsis SARL
Veristat, LLC

-
Mar-07-2022
Mar-07-2022
Merger/Acquisition
Buyer
SFL Regulatory Affairs & Scientific Communication GmbH
Veristat, LLC

-
Nov-11-2021
Nov-11-2021
Merger/Acquisition
Buyer
Drug Development and Regulation, SL
Veristat, LLC

-
Apr-07-2021
Mar-31-2021
Merger/Acquisition
Target
Veristat, LLC
WindRose Health Investors, LLC
Variance Development Partners
-
Feb-25-2021
Feb-25-2021
Merger/Acquisition
Buyer
Sqn Clinical Limited
Veristat, LLC

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-08-2023
Client Announcements
Verista Announces New Partnership with Sware to Transform Digital Validation in the Life Sciences Industry
Jun-12-2023
M&A Transaction Closings
Veristat, LLC acquired Scinopsis.
Feb-14-2023
Product-Related Announcements
Veristat Announces Supported Eight Regulatory Approvals in 2022, the Majority for Therapies Designed to Treat Rare Diseases
Oct-24-2022
Company Conference Presentations
Veristat, LLC Presents at BIO-Europe, Oct-24-2022 01:00 PM
Jun-07-2022
Executive/Board Changes - Other
Veristat, Llc Names Cindy Henderson as Chief Commercial Officer

M&A Advisors
Bryan Cave Leighton Paisner LLP, Edgemont Capital Partners, L.P., Nutter McClennen & Fish LLP


Advisors
M&A Advisors
Bryan Cave Leighton Paisner LLP, Edgemont Capital Partners, L.P., Nutter McClennen & Fish LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 18, 2023 03:44 AM
Veristat, LLC
Veristat LLC
Reports
94
GlobalData

Aug 18, 2023 04:45 AM
Veristat, LLC
Veristat LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
74
GlobalData

Jun 28, 2023 04:13 AM
Veristat, LLC
Veristat LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
73
GlobalData

Dec 14, 2022 02:36 AM
Veristat, LLC
Veristat LLC
Reports
92
GlobalData

Dec 13, 2022 03:53 AM
Veristat, LLC
Veristat LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
71
GlobalData

Sep 21, 2022 06:31 AM
Veristat, LLC
Veristat LLC
Reports
85
GlobalData

Aug 25, 2022 09:55 AM
Veristat, LLC
Veristat LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
66
GlobalData

Jun 14, 2022 03:07 AM
Veristat, LLC
Veristat LLC
Reports
83
GlobalData

May 18, 2022 03:31 AM
Veristat, LLC
Veristat LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
61
GlobalData

Mar 15, 2022 04:54 AM
Veristat, LLC
Veristat LLC
Reports
76


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Flanagan, Patrick 
Chief Executive Officer
508 429 7340
-
-
Balser, John P.
Co-Founder, President & Chief Statistical Officer
508 429 7340
-

Balser, Barbara 
Co-Founder, Chief Scientific Officer & Executive VP
508 429 7340
-

Scott, Joe 
Chief Financial Officer
508 429 7340
-

Shao, Nan 
Executive Vice President of Global Operations
508 429 7340
-

Brennan, Lauren L.
Vice President of Marketing
508 429 7340
-

Furst-Ladani, Shayesteh 
Senior VP of SFL & Head of SFL Group
508 429 7340
-

Grassis, Natalia 
Executive Vice President Global Clinical Operations & Delivery
508 429 7340
-

Henderson, Cindy 
Chief Commercial Officer
508 429 7340
-

Lukis, Lindsey 
Executive Vice President of Talent & Culture
508 429 7340
-

Madichie, Elizabeth R.
Executive Vice President of Global Regulatory Affairs
508 429 7340
-

Pelton, Colleen 
Chief Talent Officer
508 429 7340
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
